Payment overview · 2025
General Payments
$671.89
38 reported records · 19 companies
Healthcare provider profile · identity verified
Hung T Dang, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ARLINGTON, TX · NPI 1376541656
Verified facts
What the public records show
CMS Open Payments records show Hung T Dang, M.D. received $671.89 in general payments during 2025 across 38 reported records.
Amgen Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.54 | 17.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $113.70 | 16.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.78 | 9.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.14 | 5.8% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $38.33 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.89 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.77 | 4.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $31.72 | 4.7% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $27.58 | 4.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.31 | 3.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $20.62 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.26 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.15 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.99 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.67 | 2.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.90 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.99 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.09 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.46 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $671.89 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.47 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.47 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.17 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.07 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 22 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
151 | 95 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
57 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1408 | 435 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1272 | 402 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 698 | 407 |
| Fluticasone Propionate | Fluticasone Propionate | 696 | 356 |
| Metformin Hcl | Metformin Hcl | 680 | 212 |
| Celecoxib | Celecoxib | 570 | 289 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 556 | 187 |
| Azithromycin | Azithromycin | 550 | 368 |
| Pantoprazole Sodium | Pantoprazole Sodium | 490 | 237 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 481 | 147 |
| Alendronate Sodium | Alendronate Sodium | 467 | 175 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 446 | 152 |
| Tamsulosin Hcl | Tamsulosin Hcl | 446 | 140 |
| Finasteride | Finasteride | 442 | 137 |
| Montelukast Sodium | Montelukast Sodium | 419 | 234 |
| Clobetasol Propionate | Clobetasol Propionate | 415 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 138 |
| Clonidine Hcl | Clonidine Hcl | 403 | 163 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 387 | 112 |
| Prednisone | Prednisone | 373 | 256 |
| Ezetimibe | Ezetimibe | 339 | 115 |
| Glipizide | Glipizide | 317 | 98 |
| Lisinopril | Lisinopril | 298 | 102 |
| Allopurinol | Allopurinol | 292 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 291 | 102 |
| Glipizide Er | Glipizide | 276 | 88 |
| Mometasone Furoate | Mometasone Furoate | 272 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 70 |
| Ramipril | Ramipril | 238 | 83 |
| Carvedilol | Carvedilol | 218 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 73 |
| Diclofenac Sodium | Diclofenac Sodium | 205 | 95 |
| Gabapentin | Gabapentin | 200 | 108 |
| Repaglinide | Repaglinide | 196 | 65 |
| Azelastine Hcl | Azelastine Hcl | 189 | 89 |
| Telmisartan | Telmisartan | 180 | 61 |
| Januvia | Sitagliptin Phosphate | 157 | 48 |
| Prolia | Denosumab | 151 | 95 |
| Meclizine Hcl | Meclizine Hcl | 141 | 95 |
| Jardiance | Empagliflozin | 139 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 82 |
| Losartan Potassium | Losartan Potassium | 138 | 51 |
| Vascepa | Icosapent Ethyl | 137 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 46 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 133 | 99 |
| Calcitriol | Calcitriol | 130 | 53 |
| Alcohol Pads | Alcohol Antiseptic Pads | 127 | 70 |
| Furosemide | Furosemide | 120 | 69 |
| Rybelsus | Semaglutide | 118 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 117 | 44 |
| Potassium Chloride | Potassium Chloride | 117 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 45 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 115 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 114 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 42 |
| Belsomra | Suvorexant | 108 | 59 |
| Farxiga | Dapagliflozin Propanediol | 99 | 27 |
| Eliquis | Apixaban | 92 | 29 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 32 |
| Hydrocortisone | Hydrocortisone | 88 | 32 |
| Amoxicillin | Amoxicillin | 87 | 77 |
| Metformin Hcl Er | Metformin Hcl | 85 | 33 |
| Cephalexin | Cephalexin | 80 | 69 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | 25 |
| Omeprazole | Omeprazole | 79 | 27 |
| Tramadol Hcl | Tramadol Hcl | 77 | 40 |
| Dicyclomine Hcl | Dicyclomine Hcl | 76 | 46 |
| Glimepiride | Glimepiride | 74 | 25 |
| Trazodone Hcl | Trazodone Hcl | 73 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 57 |
| Spironolactone | Spironolactone | 70 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 67 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 36 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 64 | 19 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 64 | 18 |
| Indomethacin | Indomethacin | 59 | 32 |
| Restasis | Cyclosporine | 59 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 57 | 56 |
| Promethazine Hcl | Promethazine Hcl | 54 | 42 |
| Simvastatin | Simvastatin | 54 | 18 |
| Nitroglycerin | Nitroglycerin | 53 | 28 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 52 | 27 |
| Metronidazole | Metronidazole | 51 | 42 |
| Mounjaro | Tirzepatide | 51 | 14 |
| Pregabalin | Pregabalin | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 17 |
| Trulicity | Dulaglutide | 47 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 13 |
| Entecavir | Entecavir | 42 | 12 |
| Lansoprazole | Lansoprazole | 41 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 34 |
| Valacyclovir | Valacyclovir Hcl | 39 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 18 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 37 | 12 |
| Naproxen | Naproxen | 36 | 18 |
| Megestrol Acetate | Megestrol Acetate | 35 | 25 |
| Creon | Lipase/Protease/Amylase | 34 | 13 |
| Methimazole | Methimazole | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Sertraline Hcl | Sertraline Hcl | 31 | 15 |
| Zenpep | Lipase/Protease/Amylase | 31 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 11 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 26 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Fluocinonide | Fluocinonide | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | 14 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Famotidine | Famotidine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $671.89 · 38 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE, FUROSCIX, Fluad, Flucelvax, GVOKE HYPOPEN, JARDIANCE, Korlym, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, REZDIFFRA, SHINGRIX, VOQUEZNA, Xhance, ZENPEP, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error